[1]智慧 赵青 柳志红.慢性血栓栓塞性肺动脉高压发病机制新进展：从基础到临床[J].心血管病学进展,2022,(4):297-300.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]
　HUANG Zhihua,LUO Qin,ZHAO Zhihui,et al.Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension:from Bench to Bedside[J].Advances in Cardiovascular Diseases,2022,(4):297-300.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]
点击复制

慢性血栓栓塞性肺动脉高压发病机制新进展：从基础到临床()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年4期
页码:
297-300
栏目:
综述
出版日期:
2022-04-25

文章信息/Info

Title:
Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension:from Bench to Bedside
作者:
智慧 赵青 柳志红
(中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院,北京 100037)
Author(s):
HUANG Zhihua;  LUO Qin ;  ZHAO Zhihui ;  ZHAO Qing ;  LIU Zhihong
?Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037,China)
关键词:
血栓栓塞; 肺高压; 发病机制; 病理生理; 靶向药物
Keywords:
Thromboembolism; Pulmonary hypertension; Pathogenesis; Pathophysiology; Targeted drug
DOI:
10.16806/j.cnki.issn.1004-3934.2022.04.003
摘要:
慢性血栓栓塞性肺动脉高压（CTEPH）属于肺动脉高压分型的第四大类，是一种自然预后极差的慢性进展性疾病。CTEPH通常被认为是急性肺血栓栓塞症（APTE）的一种长期并发症，但研究表明部分CTEPH患者无明确的APTE既往史。因此，阐明CTEPH的发病机制，对于认识CTEPH的发生发展过程、指导疾病诊治具有重要意义。现围绕病理生理机制和靶向药物等临床治疗策略方面，总结CTEPH发病机制新进展，为CTEPH诊治提供理论依据。
Abstract:
Chronic thromboembolic pulmonary hypertension (CTEPH) belongs to the fourth category of pulmonary hypertension,and it is a chronic progressive disease with a poor natural prognosis. CTEPH is generally considered to be a long-term complication of acute pulmonary thromboembolism (APTE),but studies have shown that some patients with CTEPH do not have a history of APTE. Therefore,clarifying the pathogenesis of CTEPH is of great significance for understanding the occurrence and course of CTEPH and guiding disease diagnosis and treatment. This article summarizes the advances in the pathogenesis of CTEPH from the perspectives of pathophysiology and clinical therapeutic strategies such as targeted drugs,to provide a theoretical basis for the diagnosis and treatment of CTEPH.

参考文献/References:


[1] Papamatheakis DG,Poch DS,Fernandes TM,et al. Chronic thromboembolic pulmonary hypertension:JACC focus seminar[J]. J Am Coll Cardiol,2020,76(18):2155-2169.

[2] Pepke-Zaba J,Delcroix M,Lang I,et al. Chronic thromboembolic pulmonary hypertension(CTEPH):results from an international prospective registry[J]. Circulation,2011,124(18):1973-1981.

[3] Korkmaz A,Ozlu T,Ozsu S,et al. Long-term outcomes in acute pulmonary thromboembolism:the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors[J]. Clin Appl Thromb Hemost,2012,18(3):281-288.

[4] Alba GA,Atri D,Darbha S,et al. Chronic thromboembolic pulmonary hypertension:the bench[J]. Curr Cardiol Rep,2021,23(10):141.

[5] Wong CL,Szydlo R,Gibbs S,et al. Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension[J]. Blood Coagul Fibrinolysis,2010,21(3):201-206.

[6] Ghosh AK,Vaughan DE. PAI-1 in tissue fibrosis[J]. J Cell Physiol,2012,227(2):493-507.

[7] Morris TA. Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension:clinical and genetic insights[J]. Curr Opin Pulm Med,2013,19(5):422-429.

[8] Miniati M,Fiorillo C,Becatti M,et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic[J]. Am J Respir Crit Care Med,2010,181(9):992-996.

[9] Zabini D,Heinemann A,Foris V,et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients[J]. Eur Respir J,2014,44(4):951-962.

[10] Privratsky JR,Newman PJ. PECAM-1:regulator of endothelial junctional integrity[J]. Cell Tissue Res,2014,355(3):607-619.

[11] Kellermair J,Redwan B,Alias S,et al. Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution[J]. Blood,2013,122(19):3376-3384.

[12] Yaoita N,Shirakawa R,Fukumoto Y,et al. Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol,2014,34(11):2486-2494.

[13] Alba GA,Samokhin AO,Wang RS,et al. NEDD9 is a novel and modifiable mediator of platelet-endothelial adhesion in the pulmonary circulation[J]. Am J Respir Crit Care Med,2021,203(12):1533-1545.

[14] Zabini D,Nagaraj C,Stacher E,et al. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction[J]. PLoS One,2012,7(8):e43793.

[15] Bochenek ML,Leidinger C,Rosinus NS,et al. Activated endothelial TGFβ1 signaling promotes venous thrombus nonresolution in mice via endothelin-1:potential role for chronic thromboembolic pulmonary hypertension[J]. Circ Res,2020,126(2):162-181.

[16] Belik D,Tsang H,Wharton J,et al. Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesis[J]. J Biomed Sci,2016,23:4.

[17] Quarck R,Wynants M,Verbeken E,et al. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension[J]. Eur Respir J,2015,46(2):431-443.

[18] Dorfmüller P,Günther S,Ghigna MR,et al. Microvascular disease in chronic thromboembolic pulmonary hypertension:a role for pulmonary veins and systemic vasculature[J]. Eur Respir J,2014,44(5):1275-1288.

[19] Matusov Y,Singh I,Yu YR,et al. Chronic thromboembolic pulmonary hypertension:the bedside[J]. Curr Cardiol Rep,2021,23(10):147.

[20] Ghofrani HA,D’Armini AM,Grimminger F,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension[J]. N Engl J Med,2013,369(4):319-329.

[21] Simonneau G,D’Armini AM,Ghofrani HA,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension:a long-term extension study(CHEST-2)[J]. Eur Respir J,2015,45(5):1293-1302.

[22] Marra AM,Halank M,Benjamin N,et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension(the RIVER study)[J]. Respir Res,2018,19(1):258.

[23] Sadushi-Kolici R,Jansa P,Kopec G,et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension(CTREPH):a double-blind,phase 3,randomised controlled trial[J]. Lancet Respir Med,2019,7(3):239-248.

[24] Ja?s X,D’Armini AM,Jansa P,et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension:BENEFiT(Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension),a randomized,placebo-controlled trial[J]. J Am Coll Cardiol,2008,52(25):2127-2134.

[25] Ghofrani HA,Simonneau G,D’Armini AM,et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension(MERIT-1):results from the multicentre,phase 2,randomised,double-blind,placebo-controlled study[J]. Lancet Respir Med,2017,5(10):785-794.

[26] Escribano-Subias P,Bendjenana H,Curtis PS,et al. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension(CTEPH)[J]. Pulm Circ,2019,9(2):2045894019846433.

[27] Gabrielly M,Bourlier D,Taniguchi Y,et al. Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension(CTEPH)[J]. Eur Respir J,2018,52(suppl 62):PA3053.

[28] Kalra R,Duval S,Thenappan T,et al. Comparison of balloon pulmonary angioplasty and pulmonary vasodilators for inoperable chronic thromboembolic pulmonary hypertension:a systematic review and meta-analysis[J]. Sci Rep,2020,10(1):8870.

[29] Wiedenroth CB,Ghofrani HA,Adameit MSD,et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Pulm Circ,2018,8(3):2045894018783996.

[30] Aoki T,Sugimura K,Terui Y,et al. Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study[J]. Int J Cardiol Heart Vasc,2020,29:100579.

相似文献/References:

[1]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
　DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[2]王梓良 何一秀 林伟力 张再磊 褚银平.单纯左心耳干预预防心源性脑卒中的研究进展[J].心血管病学进展,2021,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　WANG ZiliangHE YixiuLIN WeiliZHANG ZaileiCHU Yinping.Prevention of Cardiogenic Stroke by Simple Intervention of Left Atrial Appendage[J].Advances in Cardiovascular Diseases,2021,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[3].LAmbreTM封堵器与新型口服抗凝药物预防心房颤动患者血栓栓塞事件的对照研究[J].心血管病学进展,2021,(11):1036.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　LI YahuiWANG XuewenHUANG Congxin.A Comparative Study of LAmbreTM Device and Direct Oral Anticoagulants in Preventing Thromboembolic Events in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):1036.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[4]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
　DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(4):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[5]魏志梁 孙雨可 尹月娇 孙守刚.心房颤动合并慢性肾脏病患者的左心耳封堵治疗研究进展[J].心血管病学进展,2022,(9):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
　WEI Zhiliang,SUN Yuke,YIN Yuejiao,et al.Left Atrial Appendage Closure in Patients with Atrial Fibrillation Complicated with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2022,(4):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]

更新日期/Last Update: 2022-05-13